Erythema multiforme secondary to dideoxycytidine (ddC)

[1] Fischl M.A., Olson R.M., Follansbee S.E., Et al., Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy, Ann Intern Med, 118, (1993)

[2] Merigan T.C., Skowron G., Bozzette S.A., Et al., Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections, Ann Intern Med, 110, (1989)

[3] Abrams D.I., Goldman A.I., Launer C., Et al., A comparative study of didanosine and zalcitabine after treatment with zidovudine in patients with HIV infection, N Eng J Med, 330, pp. 657-662, (1994)

[4] McNeely M.C., Yarchoan R., Broder S., Lawley T.J., Dermatologic complications associated with administration of 2′3′dideoxycytidine in patient with human immunodeficiency virus infection, J Am Acad Dermatol, 21, pp. 1213-1217, (1989)

[1] Fischl M.A., Olson R.M., Follansbee S.E., Et al., Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy, Ann Intern Med, 118, (1993)

[2] Merigan T.C., Skowron G., Bozzette S.A., Et al., Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections, Ann Intern Med, 110, (1989)

[3] Abrams D.I., Goldman A.I., Launer C., Et al., A comparative study of didanosine and zalcitabine after treatment with zidovudine in patients with HIV infection, N Eng J Med, 330, pp. 657-662, (1994)

[4] McNeely M.C., Yarchoan R., Broder S., Lawley T.J., Dermatologic complications associated with administration of 2′3′dideoxycytidine in patient with human immunodeficiency virus infection, J Am Acad Dermatol, 21, pp. 1213-1217, (1989)